GAGAL GINJAL KRONIK, SINDROM NEFROTIK DAN HIPERTENSI...

87

DAFTAR PUSTAKA

1. Corrigan JJ, Boineau GF. Hemolytic-Uremic Syndrome. Pediatrics.

2001;22:365–9.

2. Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P.

Pathophysiology and treatment of typical and atypical hemolytic uremic

syndrome typique et atypique. Pathol Biol [Internet]. 2015;63:136–43.

Available from: http://dx.doi.org/10.1016/j.patbio.2015.03.001

3. Trompeter, R.S., Schwartz, R., Chantler, C., Dillon, M.J., Haycock, G.b.,

Kay, R., Barrat TM. Haemolytic-uraemic syndrome  : an analysis of

prognostic features. Arch Dis Child Dis Child. 1983;58:101–5.

4. Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N Eng J Med.

2009;361:1676–87.

5. Dobilien, D., Mitkien, R., Medzevi, Ai., Dar, E., Jankauskien A. Long-term

follow-up of children with typical hemolytic uremic syndrome. Medicina

(B Aires). 2015;1:146–51.

6. Loirat C, Frémeaux-bacchi V. Atypical hemolytic uremic syndrome.

Orphanet J Rare Dis. 2011;6:1–30.

7. Gipson DS, Massengill SF, Yao L, Nagaraj S, William E, Mahan JD, et al.

Management of childhood onset nephrotic syndrome. Pediatrics.

2009;124:747–58.

8. Trihono P, Alatas H, T T, SO P, MS N, Soemyarso NA. Kompendium

Nefrologi Anak. In: KOMPENDIUM NEFROLOGI. 2012. p. 72–80.

9. Caletti MG, Gallo G, Gianantonio CA. Development of focal segmental

sclerosis and hyalinosis in hemolytic uremic syndrome. Pediatr Nephrol.

1996;10:687–92.

10. Geary DF. Hemolytic Uremic Syndrome. J Pediatr. 2007;151:113–4.

11. Polito MG, Kirsztajn GM. Thrombotic microangiopathies: thrombotic

thrombocytopenic purpura / hemolytic uremic syndrome. J Bras Nefrol

ʹ orgão Of Soc Bras e Latino-Americana Nefrol. 2010;32:303–15.

12. Fakhouri F, Frémeaux-bacchi V, Loirat C. Atypical hemolytic uremic

syndrome  : From the rediscovery of complement to targeted therapy. Eur

J Intern Med [Internet]. 2013;24:492–5. Available from:

http://dx.doi.org/10.1016/j.ejim.2013.05.008

13. Kavanagh D, Goodship THJ, Richards A. Atypical haemolytic uraemic

syndrome. 2006;5–22.

GAGAL GINJAL KRONIK, SINDROM NEFROTIK DAN HIPERTENSI PADA SINDROM HEMOLITIKUREMIKDESSY SHINTA MURTYUniversitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

88

14. Stergiou N, Kapogiannis A, Orfanou I, Grapsa B, Roma E. Atypical

hemolytic-uremic syndrome ( HUS ) with recovery after a long-lasting

anuria  : a case report. Hippokratia. 2011;15:90–2.

15. Siegler, R.L., Milligan MK, Burningham, T.H., Christofferson, R.D.,

Shien-young, C., Jorde LB. Long-term outcome and prognostic indicators

in the hemolytic uremic syndrome. J Pediatr. 1991;2:195–200.

16. Krishnan RG. Nephrotic syndrome. Paediatr Child Health (Oxford)

[Internet]. 2012;22:337–40. Available from:

http://dx.doi.org/10.1016/j.paed.2012.02.004

17. Beattie J. Guideline for the Management of Nephrotic Syndrome. 2007. 1-8

p.

18. Braga A. Revised guidelines for management of steroid-sensitive nephrotic

syndrome. Indian J Nephrol. 2008;18:31–9.

19. Czarniak P, Zurowska A. Treatment strategies to prevent renal damage in

hypertensive children. Curr Hypertens Rep. 2014;16:423.

20. Shults J, Ph D, Zemel BS, Ph D, Foster BJ, Stallings VA. Long-Term,

High-Dose Glucocorticoids and Bone Mineral Content in Childhood

Glucocorticoid-Sensitive Nephrotic Syndrome. 2004;868–75.

21. Roccella, E.J., Hoke, T., Hunt, C.E., Pearson G. Fourth Report On

Diagnosis , Evaluation, and Treatment of High Blood Pressure in Children

and Adolescents. 2005.

22. Ekoyan G, Lameire N, Eckardt K-U, Kasiske BL, Wheeler DC. KDIGO

clinical practice guideline for the management of blood pressure in chronic

kidney disease. Kidney Int. 2012;2:Supplements.

23. Venkataraman R, Kellum JA. Defining Acute Renal Failure  : The RIFLE

Criteria. J Intensive Care Med. 2007;22:187–93.

24. NHS Commisioning Board. Patent foramen ovale (PFO) closure. 2013. 1-

23 p.

25. Park MK, Salamat M. Park’s the pediatric cardiology handbook  : fifth

edition. 2016. 237 p.

26. Whyte DA, Fine RN. Chronic kidney disease in children. Pediatr Rev.

2008;29:335–41.

27. Warady BA, Donna S, Foster B, Goldstein SL, Frederick K, Sarah E L, et

al. KDOQI clinical practice guideline for nutrition in children with chronic

kidney disease. Am J Kidney Dis. 2009;53:Suppl 2.

28. Ekoyan G, Lameire N, Eckardt K-U, Kasiske BL, Wheeler DC. KDIGO


89

2012 clinical practice guideline for the evaluation and management of

chronic kidney disease. Kidney Int. 2013;3:Supplements.

29. Cobeñas CJ, Alconcher LF, Spizzirri AP, Rahman RC. Long-term follow-

up of Argentinean patients with hemolytic uremic syndrome who had not

undergone dialysis. Pediatr Nephrol. 2007;22:1343–7.

30. Davis PB. Hemolytic Uremic Syndrome and. 2007;113–4.

31. Noris M, Remuzzi G. Glomerular diseases dependent on complement

activation. Am J Kidney Dis [Internet]. 2015;66:359–75. Available from:

http://dx.doi.org/10.1053/j.ajkd.2015.03.040

32. Hernández R. How to treat corticosteroid-resistant idiopathic focal

segmental glomerulosclerosis  ? Nefrologia. 2011;31:247–50.

33. Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Adv Pediatr

[Internet]. 2015;61:335–56. Available from:

http://dx.doi.org/10.1016/j.yapd.2014.04.001

34. Taylor, C. M., Machin, S., Wigmore S. Clinical Practice Guideline for the

Management of Atypical Haemolytic Uraemic Syndrome in the United

Kingdom. :1–22.

35. Yap H-K, Liu ID, Tay W-C. Pediatric nephrology on the go. 2012. 167-185

p.

36. Mahan JD, Warady BA. Assessment and treatment of short stature in

pediatric patients with chronic kidney disease  : a consensus statement.

Pediatr Nephrol. 2006;21:917–30.

37. Bakr A, Amr M, Sarhan A, Hammad A, Ragab M. Psychiatric disorders in

children with chronic renal failure. Pediatr Nephrol. 2007;22:128–31.

38. Mckenna AM, Keating LE, Vigneux A, Stevens S, Williams A, Geary DF.

Quality of life in children with chronic kidney disease — patient and

caregiver assessments. Nephro Dial Transpl. 2006;21:1899–905.

39. Sealy L, Inward C, Burren C, Smith Trace. Growth Monitoring Guidelines

for Children with Chronic Kidney Disease. Bristol Royal Hospital for

Children. 2011. p. 1–7.

40. Stanbury RM, Graham EM. Systemic corticosteroid therapy — side efects

and their management. 1998;704–8.

41. Murphy M. The PSC-17  : a brief Pediatric Symptom Checklist with

psychosocial problem subscales. Ambul Child Heal. 1999;5:225–36.

42. Departemen Kesehatan RI. Pedoman Teknis Penilaian Rumah Sehat. Vol.

1. 2002. 22 p.


90

43. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height ,

weight , height velocity , weight velocity , and stages of puberty. Arch Dis

Child. 1976;51:170–9.

44. Salas P, Pinto V, Rodriguez J, Zambrano MJ, Mericq V. Growth

retardation in children with kidney disease. Int J Endocrinol. 2013;13:1–9.

45. Seikaly MG, Salhab N, Gipson D. Stature in children with chronic kidney

disease  : analysis of NAPRTCS database. Pediatr Nephrol. 2006;21:793–

9.

46. Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR. Growth

failure , risk of hospitalization and death for children with end-stage renal

disease. Pediatr Nephrol. 2002;17:450–5.

47. Modini VM, Seikaly MG. Growth in Children After Renal Transplantation:

An Update. Dial Transplant. 2010;39:516–21.

48. Mekahli D, Shaw V, Ledermann SE, Rees L. Longterm outcome of infants

with severe chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:1–8.

49. Foster BJ, Leonard MB. Measuring nutritional status in children with

chronic kidney disease 1 – 3. Am J Clin Nutr. 2004;80:801–14.

50. Rees L, Mak RH. Nutrition and growth in children with chronic kidney

disease. Nat Publ Gr [Internet]. 2011;7:615–23. Available from:

http://dx.doi.org/10.1038/nrneph.2011.137

51. Rahajoe NN, Basir D, Makmuri MS, Kartasasmita CB. Pedoman Nasional

Tuberkulosis Anak. 2007. 47-66 p.

52. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome:

mechanisms and consequences. Kidney Int [Internet]. 2016;1–12. Available

from: http://dx.doi.org/10.1016/j.kint.2016.02.026

53. Willis K, Cheung M, Slifer S. KDIGO clinical practice guideline for lipid

management in chronic kidney disease. Kidney Int. 2013;3.

54. Vivante A, Calderon-margalit R, Skorecki K. Hematuria and risk for end-

stage kidney disease. Curr Opin Nephrol Hypertens. 2013;22:325–30.

55. Lin HY, Yen C, Lim L, Hwang D, Tsai J, Hwang S, et al. Microscopic

Haematuria and Clinical Outcomes in Patients With Stage 3 – 5

Nondiabetic Chronic Kidney Disease. Nat Publ Gr [Internet]. 2015;5:1–10.

Available from: http://dx.doi.org/10.1038/srep15242

56. Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, et al.

Anemia and Risk of Hospitalization in Pediatric Chronic Kidney Disease.

Clin J Am Soc Nephrol. 2009;4:48–56.


91

57. Willis K, Cheung M, Slifer S. KDIGO clinical practice guideline for

anemia in chronic kidney disease. Kidney Int. 2012;2.

58. Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-perry K. The

consequences of chronic kidney disease on bone metabolism and growth in

children. Nephrol Dial Transpl. 2012;27:3063–71.

59. Shaman AM, Kowalski SR. Hyperphosphatemia Management in Patients

with Chronic Kidney Disease. Saudi Pharm J [Internet]. 2016;24:494–505.

Available from: http://dx.doi.org/10.1016/j.jsps.2015.01.009

60. Martin KJ, Gonza EA. Prevention and control of phosphate retention

/hyperphosphatemia in CKD-MBD. Clin J Am Soc Nephrol. 2011;6:440–6.

61. Wesseling-perry K, Salusky IB. Chronic Kidney Disease  : Mineral and

Bone Disorder in Children. Semin Nephrol. 2014;33:169–79.

62. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney

disease in children. Clin Kidney J. 2016;9:583–91.

63. Ketteler M, Wüthrich RP, Floege J. Management of hyperphosphataemia in

chronic kidney disease — challenges and solutions. Clin Kidney J.

2013;23:128–36.

64. Ekoyan G, Eckardt K-U, Kasiske BL, Moe SM, Drucke TB, Block GA.

KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation,

Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone

Disorder ( CKD-MBD ). Kidney Int. 2009;76:121–30.

65. Lau WL, Kalantar-Zadeh K, Kovesdy CP MR. Alkaline phosphatase  :

Better than PTH as a marker of cardiovascular and bone disease  ?

Hemodial Int. 2014;18:720–4.

66. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, Mcallister CJ, et

al. Serum Alkaline Phosphatase Predicts Mortality among Maintenance

Hemodialysis Patients. J Am Soc Nephrol. 2008;19:2193–203.

67. Shankar O, Sah P, Qing YX. Associations between hyperuricemia and

chronic kidney disease  : a review. Nephro Urol Mon. 2015;7:e272333.

68. Johnson RJ, Nakagawa T, Jalal D, Sánchez-lozada LG, Kang D, Ritz E.

Uric acid and chronic kidney disease  : which is chasing which  ? Nephrol

Dial Transpl. 2013;28:2221–8.

69. Goicoechea M, Vinuesa SG De, Verdalles U, Ruiz-caro C, Ampuero J,

Rinco A, et al. Effect of allopurinol in chronic kidney disease progression

and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.

70. Shah SN, Abramowitz MK, Hostetter TH, Melamed ML. Serum bicarbonat

levels and progression of kidney disease  : cohort study. Am J Kidney Dis.


92

2015;54:270–7.

71. Kraut JA, Madias NE. Metabolic Acidosis of CKD  : An Update. Am J

Kidney Dis [Internet]. 2016;67:307–17. Available from:

http://dx.doi.org/10.1053/j.ajkd.2015.08.028

72. Menon V, Tighiouart H, Vaughn NS. Serum bicarbonate and long-term

outcomes in CKD. Am J Kidney Dis [Internet]. 2010;56:907–14. Available

from: http://dx.doi.org/10.1053/j.ajkd.2010.03.023

73. Kovesdy CP, Anderson JE, Kalantar-zadeh K. Association of serum

bicarbonate levels with mortality in patients with non-dialysis-dependent

CKD. Nephrol Dial Transpl. 2008;24:265–8.

74. Chen W, Abramowitz MK. Metabolic acidosis and the progression of

chronic kidney disease. BMC Nephrol. 2014;15:1–8.

75. Aldigier JC, Kanjanbuch T, Ma L, Brown NJ, Fogo AB. Regression of

existing glomerulosclerosis by inhibition of aldosterone. J Am Soc

Nephrol. 2005;16:3306–14.

76. Yaqoob MM. Treatment of Acidosis in CKD. Clin J Am Soc Nephrol.

2013;8:342–3.

77. Scialla JJ, Anderson CAM. Dietary acid load: a novel nutritional target in

chronic kidney disease. Adv Chronic Kidney. 2014;20:141–9.

78. Adeva-andany MM, Fernández-fernández C, Mouriño-bayolo D, Castro-

quintela E, Domínguez-montero A. Sodium Bicarbonate Therapy in

Patients with Metabolic Acidosis. Sci World J. 2014;2014:1–14.

79. Mathews T, Minifio AM, Osterman MJ, Strobino DM, Guyer B. Annual

Summary of Vital Statistics  : 2008. Pediatrics. 2008;127:146–57.

80. Collins AJ, Foley RN, Chavers B, Gilbertson D. US Renal Data System

2011 Annual Data Report. Am J Kidney Dis. 2012;59:supplement.

81. Kumar P, O’Connor NR. Conservative Management of End-Stage Renal

Disease without Dialysis  : A Systematic Review. J Palliat Med.

2012;15:228–35.

82. Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney

disease. 2008;27–39.

83. Jaap W Groothoff, Gruppen MP, Offringa M, Hutten J, Lilien MR, Kar NJ

Van de, et al. Mortality and causes of death of end-stage renal disease in

children  : A Dutch cohort study. Kidney Int. 2002;61:621–9.

84. Mcdonald SP, Craig JC. Long-Term Survival of Children with End-Stage

Renal Disease. N Eng J Med. 2004;350:2654–62.


93

85. Scavarda VT, Andrade M De, Carvalho AC, Moises VA. Children with

chronic renal disease undergoing dialysis or conservative treatment –

differences in structural and functional echocardiographic parameters.

Echocardiography. 2014;23:1131–7.


94


GAGAL GINJAL KRONIK, SINDROM NEFROTIK DAN HIPERTENSI...

Documents

Transcript of GAGAL GINJAL KRONIK, SINDROM NEFROTIK DAN HIPERTENSI...